Annals of Oncology Advance Access originally published online on April 11, 2005
Annals of Oncology 2005 16(6):958-965; doi:10.1093/annonc/mdi178
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
1 Section of Hematology and Oncology, University of Chicago, Chicago, USA; 2 Committee on Clinical Pharmacology and Pharmacogenomics; 3 University of Chicago Cancer Research Center, Chicago, USA and 4 Lorus Therapeutics, Toronto, Canada
*Correspondence to: Dr R. L. Schilsky, MD, Biological Sciences Division, University of Chicago, 5841 S. Maryland Ave, MC 1000, Chicago, IL 60 637, USA. Tel: +1-773-834-3914; Fax: +1-773-834-3915; Email: rschilsk{at}medicine.bsd.uchicago.edu
Background:: This study of GTI-2040, a 20-mer phosphorothioate oligonucleotide complementary to the messenger ribonucleic acid (mRNA) of the R2 subunit of ribonucleotide reductase (RNR), was conducted to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of the agent in patients with advanced solid tumors or lymphoma. Plasma pharmacokinetics of GTI-2040 and suppression of RNR expression in peripheral blood mononuclear cells were also studied.
Patients and methods:: GTI-2040 was administered as a continuous intravenous infusion for 21 days every 4 weeks. Dose escalation was performed using an accelerated, dose-doubling schedule until any drug related toxicity
grade 2 was observed; subsequent dose escalation followed a more conservative dose escalation scheme with three patients/cohort.
Results:: A total of 49 cycles of therapy were administered to 36 patients at GTI-2040 doses ranging from 18.5 mg/m2/day to 222 mg/m2/day. GTI-2040 was generally well tolerated. At the highest dose level examined, two patients experienced dose limiting reversible hepatic toxicity. Constitutional toxicities consisting of fatigue and anorexia were the most common toxicities.
Conclusions:: The recommended dose of GTI-2040 given on this infusion schedule is 185 mg/m2/day. GTI-2040 appears to have a manageable toxicity profile and is generally well tolerated as a single agent.
Key words: antisense therapies, GTI-2040, pharmacokinetics, phase I trial, phosphorothioate oligonucleotides, ribonucleotide reductase inhibition
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. B. Klisovic, W. Blum, X. Wei, S. Liu, Z. Liu, Z. Xie, T. Vukosavljevic, C. Kefauver, L. Huynh, J. Pang, et al. Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia Clin. Cancer Res., June 15, 2008; 14(12): 3889 - 3895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-L. Devlin, P. C. Mack, R. A. Burich, P. H. Gumerlock, H.-J. Kung, M. Mudryj, and R. W. deVere White Impairment of the DNA Repair and Growth Arrest Pathways by p53R2 Silencing Enhances DNA Damage-Induced Apoptosis in a p53-Dependent Manner in Prostate Cancer Cells Mol. Cancer Res., May 1, 2008; 6(5): 808 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Heidel, J. Y.-C. Liu, Y. Yen, B. Zhou, B. S.E. Heale, J. J. Rossi, D. W. Bartlett, and M. E. Davis Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo Clin. Cancer Res., April 1, 2007; 13(7): 2207 - 2215. [Abstract] [Full Text] [PDF]
|
|